The buttoned-up biotech, recently valued at $7bn, has finally unveiled plans to go public. But investor appetite for new issues has taken a knock. Does Moderna’s move…
Almost $2bn was raised by drug developers in the third quarter, a period that witnessed two of the largest flotations of pre-revenue companies in recent years.
Nine IPOs have got away so far this year, and one of them is very big indeed.
Biotech IPOs raised a huge $2.3bn on Western exchanges in the second-quarter of 2018, as private companies rushed to market ahead of the summer lull.
Biotech IPOs record another strong quarter, setting the pace for a bumper year of new issues.
Highly unusually most of the cash raised via IPOs in 2017 came via offerings outside the US.
Biotechs raised $3.9bn in IPOs across 2017, signalling that investor interest in new issues has returned.
Another billion dollar quarter for biotech IPOs signals that investor appetite for high-risk offerings is strong.
The biotech IPO market records its first billion dollar quarter in two years as demand for new issues recovers.